Clinical Trial Update: A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for RC48-ADC in advanced melanoma with HER2 variant/mutation/amplification/overexpression is ongoing, with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Melanoma, Stage II, HER2-positive | Phase 2 | Status: UNKNOWN